German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence

Press Releases

<< Back
March 9, 2016 at 8:00 AM EST

German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence

REDWOOD CITY, Calif., March 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the update of the German Association of Gynecological Oncology's (AGO's) treatment guidelines to recognize Oncotype DX® as the only multi-gene breast cancer test with the highest 1A level of evidence. The AGO guidelines also reconfirmed Oncotype DX as the only multi-gene expression test validated to provide predictive information on the likelihood of chemotherapy benefit for women with early-stage, hormone-receptor positive, HER2-negative invasive breast cancer.

"The latest update by AGO supports public reimbursement in Germany, one of our key European markets, and furthers international growth as we continue to bring precision medicine to breast cancer patients worldwide," said Jim Vaughn, R.Ph. Chief Commercial Officer, Genomic Health. "Together with a recently established access program by the National Health Service in England and existing public reimbursement for the Oncotype DX breast cancer test in Switzerland, Ireland, Greece and Spain, we continue to pioneer the delivery of value-based testing to healthcare systems across Europe."

The updated AGO guidelines reflect newly published large prospective Oncotype DX outcomes studies including TAILORx, conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI), and three-year data from the PlanB study, conducted by the West German Study Group (WSG). Five-year results from PlanB will be presented on Friday, March 11 at a plenary session during the 10thEuropean Breast Cancer Conference (EBCC-10).

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With 600,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX breast cancer tests, visit: or

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, and follow the company on Twitter: @GenomicHealthFacebookYouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's ability to obtain or maintain public and private reimbursement in key markets in the U.S. and abroad; the ability of test results to change treatment decisions; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filing with the Securities and Exchange Commission , including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Genomic Health, Inc. logo.

Logo -      


To view the original version on PR Newswire, visit:

SOURCE Genomic Health, Inc.

News Provided by Acquire Media